IntelliCentrics Global Holdings Ltd. informed the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended December 31, 2020 and other information currently available to the Company, the unaudited consolidated financial results of the Group for the six months ended December 31, 2020 are expected to record a net loss of approximately USD 1.4 million compared to a net profit of USD 2.4 million for the six months ended December 31, 2019. The net loss was mainly attributable to a significant increase in amortization and depreciation related to significant platform solution development capitalized in the prior fiscal year. Additionally, non-capitalized research and development expenses relating to platform enhancements and new services increased. Non-capitalized enhancements include an upgraded compliance survey capability in SEC 3URE and the industry's first COVID-19 credential. Despite a slight increase in revenue during the same periods, the overall demand for healthcare over the reporting period has declined. This decline is mainly attributable to COVID-19, resulting in an unprecedented backlog of demand, as disease and chronic health issues remain constant. The main impact on the Group has been a softening of the average number of subscribers during the reporting period, as subscribers tend to delay their purchase or renewal of services until they are able to or have the need to enter the relevant locations of care under COVID-19 measures. As a result, total number of subscribers has decreased and may continue to decrease until most healthcare organizations fully resume their normal operations.